Egetis Therapeutics AB (publ) (STO:EGTX)

Egetis Therapeutics AB Revenue

Egetis Therapeutics AB had revenue of 13.40M SEK in the quarter ending March 31, 2026, with 5.51% growth. This brings the company's revenue in the last twelve months to 63.10M, up 35.12% year-over-year. In the year 2025, Egetis Therapeutics AB had annual revenue of 62.40M with 35.36% growth.

• Revenue (ttm): 63.10M
• Revenue Growth: +35.12%
• P/S Ratio: 38.01
• Revenue / Employee: 1.50M
• Employees: 42
• Market Cap: 2.40B

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	62.40M	16.30M	35.36%
Dec 31, 2024	46.10M	-11.50M	-19.97%
Dec 31, 2023	57.60M	35.00M	154.87%
Dec 31, 2022	22.60M	-15.60M	-40.84%
Dec 31, 2021	38.20M	-2.46M	-6.05%

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

May 4, 2026

Data Sources Report a data error